

**COPY**

Docket #PF-0114 US

**DECLARATION AND POWER OF ATTORNEY FOR  
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

**TWO NOVEL HUMAN NSP-LIKE PROTEINS**

the specification of which:

     / is attached hereto.

  X   / was filed on August 12, 1996 as application Serial No. 08/700,607  
and if this box contains an X      /, was amended on                                     

  \_   / was filed as Patent Cooperation Treaty international application No.              on  
          , 19    , if this box contains an X   \_   /, was amended on under Patent Cooperation  
Treaty Article 19 on            19    , and if this box contains an X   \_   /, was amended on               
                                    .

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Country	Number	Filing Date	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)

I hereby appoint the following:

**LUCY J. BILLINGS**  
**MICHAEL C. CERRONE**

**Registration No. 36,749**  
**Registration No. 39,132**

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

**LUCY J. BILLINGS, ESQ.**  
**INCYTE PHARMACEUTICALS, INC.**  
**3174 PORTER DRIVE, PALO ALTO, CA 94304**

**TEL: 415-855-0555      FAX: 415-845-4166**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment; or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**\*IMPORTANT:** Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

**Sole Inventor or**

**First Joint Inventor:**

Full name: **Olga Bandman**

Signature: Olga Bandman

Date: October 11, 1996

Citizenship: United States of America

Residence: Mountain View, California

P.O. Address: 2309 Rock Street, No. 27  
Mountain View, California 94043

**Second Joint Inventor:**

Full name: **Janice Au-Young**

Signature: Janice Au-Young

Date: October 21, 1996

Citizenship: United States of America

Residence: Berkeley, California

P.O. Address: 1419 Kains Avenue  
Berkeley, California 94702

**Third Joint Inventor:**

Full name: **Surya K. Goli**  
Signature: Surya Kunnari  
Date: 10 | 11 | .1996  
Citizenship: **India**  
Residence: **Sunnyvale, California**  
P.O. Address: **620 Iris Avenue, No. 338**  
**Sunnyvale, California 94086**

**Fourth Joint Inventor:**

Full name: **Jennifer L. Hillman**  
Signature: Jennifer L. Hillman  
Date: October .1996  
Citizenship: **United States of America**  
Residence: **San Jose, California**  
P.O. Address: **467 N. 3rd Street, Apt. #3**  
**San Jose, California 95112**

Certificate of Mailing

"Certificate of Express Mail" mailing label number EV 332 010 524 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 12, 2006.

By: Printed: Lyza Fimular**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of: **Bandman et al.**Title: **TWO NOVEL HUMAN NSP-LIKE PROTEINS**Serial No.: **To Be Assigned**

Filing Date:

**Herewith**Examiner: **To Be Assigned**

Group Art Unit:

**To Be Assigned**

Mail Stop: Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),  
REVOCATION OF POWER OF ATTORNEY AND  
APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8207, Frame 0208, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749
Jenny Buchbinder	Reg. No. 48,588
Diana Hamlet-Cox	Reg. No. 33,302
Joel Harris	Reg. No. 44,743
Richard C. Ekstrom	Reg. No. 37,027
Karin M. Gerstin	Reg. No. 54,119
Barrie D. Greene	Reg. No. 46,740
Lori L. Kerber	Reg. No. 41,113
Gina C. Nellesen	Reg. No. 52,062
Shirley A. Recipon	Reg. No. 47,016
Cathleen M. Rocco	Reg. No. 46,172
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
James M. Verna	Reg. No. 33,287
Yu-Mei Eureka Wang	Reg. No. 50,510

**Please direct all correspondence to:**

Legal Department  
Incyte Corporation  
3160 Porter Drive  
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Incyte Corporation,  
Phone: (650) 845-4639, Fax: (650) 849-8886 or (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE CORPORATION

Date: September 12, 2003

By: Lee Bendekgey  
Lee Bendekgey  
EVP, General Counsel/Corporate Secretary

**Department of Energy**

Washington, DC 20585

**MAR 3 2003**

Mr. Michael Carone  
Office of Licensing and Review  
U.S. Patent and Trademark Office  
Technology Group 3600  
Crystal Park 5  
Arlington, Virginia

Re: Blanket Exemption from Requirements Under §42 U.S.C. 2182 for Incyte  
Genomics, Inc.

Dear Mr. Carone:

The U.S. Department of Energy (DOE) wished to grant Incyte Genomics, Inc. (Incyte) a blanket exemption from the requirements under §42 U.S.C. 2182 for their patent applications disclosing inventions involving radionuclides. This blanket exemption is granted based on assertions set forth in Incyte's letter to DOE dated February 25, 2003. No blanket exemption is granted from the requirements of any other statute, including the security review statute, §42 U.S.C. 2181.

This blanket exemption will be effective from the date of this letter for one (1) calendar year (the "Blanket Exemption Period"), and covers all Incyte patent applications now pending before the U.S. Patent and Trademark Office and will cover all Incyte patent applications filed within the Blanket Exemption Period. Therefore, the Blanket Exemption Period ends on February 26, 2004. For the Blanket Exemption Period, Incyte will include a copy of this letter with all applicable applications. This blanket exemption may be renewed for successive one (1) year periods upon Incyte's request, subject to DOE approval. DOE will notify your office in writing of such renewals, if granted.

Sincerely,

A handwritten signature in black ink, appearing to read "Paul A. Gottlieb".

Paul A. Gottlieb  
Assistant General Counsel  
for Technology Transfer  
and Intellectual Property  
(202) 586-2802

